Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Private Equity Fund IRRs Disclosed But Questions Linger

This article was originally published in Start Up

Executive Summary

Kicking and screaming, venture capital is being dragged into maturity. Demands are growing for greater disclosure in this secretive world. And with venture funds seeming to require more and more money, the VCs may not be able to resist the trend.

You may also be interested in...



Early-Stage Biopharma Investors Opt for Safer Bets in 2002

Discovery risk is for VCs like yesterday's newspaper. With the Big Pharma market for discovery tools abysmally quiet, early-stage funding for such firms saw a steep decline.

Early-Stage Biopharma Investors Opt for Safer Bets in 2002

Discovery risk is for VCs like yesterday's newspaper. With the Big Pharma market for discovery tools abysmally quiet, early-stage funding for such firms saw a steep decline.

Freedom of Information Litigation Puts the Spotlight on Valuation Practices

VC concern over efforts to compel public pension funds to disclose information regarding their private equity partners has largely focused on the release of internal rate of return statistics. A recent court ruling, however, suggests that the legal grounds for protecting the confidentiality of such data are tenuous at best. The more significant question is whether public pension funds can be forced to disclose their venture fund investees' valuations of individual portfolio companies. Public dissemination of that information would reveal the inconsistent (and possibly arbitrary) methods use to value companies.

Topics

UsernamePublicRestriction

Register

SC090530

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel